Trial intelligence / Profile preview

Phase II study of dasatinib in accelerated phase chronic myeloid leukemia resistant or intolerant to imatinib

2004-002515-89Phase 2Completed

Sponsor

Bristol Myers Squibb

Start

Nov 2004

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1